Taro Pharmaceutical Industries Ltd. (TARO)

$42.21

-0.02

(-0.05%)▲

Live

Insights on Taro Pharmaceutical Industries Ltd.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 148.20M → 157.14M (in $), with an average increase of 5.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 8.54M → 20.20M (in $), with an average increase of 57.7% per quarter

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 44.8% return, outperforming this stock by 88.9%

Performance

  • $42.14
    $42.23
    $42.21
    downward going graph

    0.17%

    Downside

    Day's Volatility :0.2%

    Upside

    0.04%

    downward going graph
  • $24.39
    $45.76
    $42.21
    downward going graph

    42.22%

    Downside

    52 Weeks Volatility :46.7%

    Upside

    7.76%

    downward going graph

Returns

PeriodTaro Pharmaceutical Industries Ltd.Sector (Health Care)Index (Russel 2000)
3 Months
0.21%
1.9%
0.0%
6 Months
26.06%
10.7%
0.0%
1 Year
65.22%
4.6%
-1.1%
3 Years
-43.94%
14.2%
-22.1%

Highlights

Market Capitalization
1.6B
Book Value
$47.34
Earnings Per Share (EPS)
1.22
PE Ratio
34.64
PEG Ratio
0.0
Wall Street Target Price
43.0
Profit Margin
7.48%
Operating Margin TTM
10.7%
Return On Assets TTM
1.03%
Return On Equity TTM
2.61%
Revenue TTM
610.8M
Revenue Per Share TTM
16.25
Quarterly Revenue Growth YOY
12.9%
Gross Profit TTM
293.1M
EBITDA
68.9M
Diluted Eps TTM
1.22
Quarterly Earnings Growth YOY
1.78
EPS Estimate Current Year
1.1
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.3
EPS Estimate Next Quarter
0.31

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Taro Pharmaceutical Industries Ltd.(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1.87%

Current $42.21
Target $43.00

Company Financials

FY18Y/Y Change
Revenue
661.9M
↓ 24.73%
Net Income
211.2M
↓ 53.73%
Net Profit Margin
31.9%
↓ 19.99%
FY19Y/Y Change
Revenue
669.9M
↑ 1.21%
Net Income
281.8M
↑ 33.45%
Net Profit Margin
42.06%
↑ 10.16%
FY20Y/Y Change
Revenue
644.8M
↓ 3.75%
Net Income
244.2M
↓ 13.32%
Net Profit Margin
37.88%
↓ 4.18%
FY21Y/Y Change
Revenue
549.0M
↓ 14.86%
Net Income
-400.7M
↓ 264.08%
Net Profit Margin
-73.0%
↓ 110.88%
FY22Y/Y Change
Revenue
561.3M
↑ 2.25%
Net Income
58.3M
↓ 114.54%
Net Profit Margin
10.38%
↑ 83.38%
FY23Y/Y Change
Revenue
573.0M
↑ 2.07%
Net Income
25.4M
↓ 56.33%
Net Profit Margin
4.44%
↓ 5.94%
Q3 FY22Q/Q Change
Revenue
130.5M
↓ 8.91%
Net Income
-2.8M
↓ 110.26%
Net Profit Margin
-2.16%
↓ 21.29%
Q4 FY22Q/Q Change
Revenue
139.2M
↑ 6.67%
Net Income
7.3M
↓ 358.27%
Net Profit Margin
5.22%
↑ 7.38%
Q1 FY23Q/Q Change
Revenue
146.6M
↑ 5.31%
Net Income
6.9M
↓ 4.85%
Net Profit Margin
4.72%
↓ 0.5%
Q2 FY23Q/Q Change
Revenue
158.9M
↑ 8.4%
Net Income
10.0M
↑ 45.13%
Net Profit Margin
6.31%
↑ 1.59%
Q3 FY23Q/Q Change
Revenue
148.2M
↓ 6.73%
Net Income
8.5M
↓ 14.81%
Net Profit Margin
5.77%
↓ 0.54%
Q4 FY23Q/Q Change
Revenue
157.1M
↑ 6.03%
Net Income
20.2M
↑ 136.43%
Net Profit Margin
12.86%
↑ 7.09%
FY18Y/Y Change
Total Assets
2.4B
↑ 6.27%
Total Liabilities
222.8M
↑ 3.18%
FY19Y/Y Change
Total Assets
2.1B
↓ 12.24%
Total Liabilities
224.2M
↑ 0.63%
FY20Y/Y Change
Total Assets
2.3B
↑ 9.64%
Total Liabilities
231.5M
↑ 3.25%
FY21Y/Y Change
Total Assets
2.4B
↑ 2.8%
Total Liabilities
711.4M
↑ 207.32%
FY22Y/Y Change
Total Assets
2.2B
↓ 9.58%
Total Liabilities
464.9M
↓ 34.65%
FY23Y/Y Change
Total Assets
2.1B
↓ 1.88%
Total Liabilities
404.7M
↓ 12.96%
Q3 FY22Q/Q Change
Total Assets
2.1B
↓ 3.17%
Total Liabilities
401.0M
↓ 13.75%
Q4 FY22Q/Q Change
Total Assets
2.1B
↑ 0.49%
Total Liabilities
397.6M
↓ 0.85%
Q1 FY23Q/Q Change
Total Assets
2.1B
↑ 0.85%
Total Liabilities
404.7M
↑ 1.78%
Q2 FY23Q/Q Change
Total Assets
2.1B
↓ 0.02%
Total Liabilities
396.5M
↓ 2.01%
Q3 FY23Q/Q Change
Total Assets
2.1B
↓ 0.73%
Total Liabilities
371.9M
↓ 6.2%
Q4 FY23Q/Q Change
Total Assets
2.2B
↑ 2.06%
Total Liabilities
384.1M
↑ 3.27%
FY18Y/Y Change
Operating Cash Flow
323.7M
↓ 26.02%
Investing Cash Flow
-241.6M
↑ 105.16%
Financing Cash Flow
-107.0M
↓ 63.72%
FY19Y/Y Change
Operating Cash Flow
323.7M
↑ 0.01%
Investing Cash Flow
257.1M
↓ 206.41%
Financing Cash Flow
-588.8M
↑ 450.4%
FY20Y/Y Change
Operating Cash Flow
271.6M
↓ 16.1%
Investing Cash Flow
-298.2M
↓ 215.95%
Financing Cash Flow
-27.0M
↓ 95.42%
FY21Y/Y Change
Operating Cash Flow
45.8M
↓ 83.15%
Investing Cash Flow
67.7M
↓ 122.72%
Financing Cash Flow
-24.2M
↓ 10.33%
FY22Y/Y Change
Operating Cash Flow
-158.7M
↓ 446.73%
Investing Cash Flow
-170.6M
↓ 351.81%
Financing Cash Flow
-24.9M
↑ 3.05%
Q3 FY22Q/Q Change
Operating Cash Flow
20.4M
↓ 50.65%
Investing Cash Flow
-70.8M
↓ 303.69%
Financing Cash Flow
0.0
↓ 100.0%

Technicals Summary

Sell

Neutral

Buy

Taro Pharmaceutical Industries Ltd. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd.
-0.02%
26.06%
65.22%
-43.94%
-60.5%
Viatris Inc.
Viatris Inc.
-3.97%
24.7%
21.76%
-16.16%
-30.48%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-0.11%
28.23%
35.27%
41.85%
77.04%
Catalent, Inc.
Catalent, Inc.
-0.66%
31.9%
24.68%
-51.57%
26.05%
Zoetis Inc.
Zoetis Inc.
-10.88%
-10.51%
-15.19%
-11.92%
47.93%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.24%
1.82%
-5.93%
13.5%
13.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd.
34.64
34.64
0.0
1.1
0.03
0.01
NA
47.34
Viatris Inc.
Viatris Inc.
225.0
225.0
NA
2.78
0.0
0.03
0.04
17.05
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
53.44
53.44
0.44
4.78
0.13
0.09
NA
22.61
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Zoetis Inc.
Zoetis Inc.
28.76
28.76
2.58
5.8
0.5
0.13
0.01
10.9
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.86
29.86
1.69
0.45
0.07
0.04
0.03
1.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd.
Buy
$1.6B
-60.5%
34.64
7.48%
Viatris Inc.
Viatris Inc.
Hold
$13.4B
-30.48%
225.0
0.35%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.3B
77.04%
53.44
13.23%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
26.05%
211.02
-31.77%
Zoetis Inc.
Zoetis Inc.
Buy
$66.5B
47.93%
28.76
27.43%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.2B
13.5%
29.86
9.28%

Institutional Holdings

  • Krensavage Asset Management, LLC

    1.72%

  • BlackRock Inc

    1.66%

  • Renaissance Technologies Corp

    1.54%

  • Dimensional Fund Advisors, Inc.

    1.45%

  • Brandes Investment Partners & Co

    1.27%

  • Ameriprise Financial Inc

    0.82%

Company Information

established in 1950, taro pharmaceutical industries ltd. is a research-based, international, specialty pharmaceutical company that develops, manufactures and markets prescription and over-the-counter pharmaceutical products. taro’s research programs and niche strategy have enabled the company to achieve gross margins that are among the highest in the specialty pharmaceutical sector.

Organization
Taro Pharmaceutical Industries Ltd.
Employees
1554
CEO
Mr. Uday V. Baldota
Industry
Health Technology

Discover More

FAQs